 |
|
Commentary highlights impact of food-cancer drug interactions
July 18, 2007Explores approach for reducing dose of oral targeted cancer therapies
Alexandria, Va. - A commentary in the Journal of Clinical Oncology (JCO) urges researchers to explore an intriguing approach to reduce the dose, and therefore the cost, of oral targeted cancer therapies. The commentary, by Mark Ratain, MD and Ezra Cohen, MD of the University of Chicago, examines recent pharmacologic research which found that taking the targeted therapy lapatinib (Tykerb) with food significantly increased the concentration of the drug in the body. The commentary suggests that taking lapatinib with food instead of on an empty stomach, as currently indicated, could cut the needed dose by at least 60 percent, reducing the cost accordingly. The authors stress that formal studies are needed to determine the effectiveness of this approach. The article is being published online July 16.
The commentary focuses on a study presented at the March 2007 meeting of the American Society for Clinical Pharmacology and Therapeutics, which found that lapatinib is more readily absorbed by the body when taken with food, particularly a high-fat meal. As a result, 500 mg of lapatinib taken with food may be as effective as taking the currently approved 1,250 mg without food.
Lapatinib was approved by the U.S. Food and Drug Administration (FDA) in March of this year for women with advanced HER2-positive breast cancer. The FDA approved the 1,250 mg dose of lapatinib based on a large phase III clinical trial demonstrating its effectiveness and safety at that dose without food. It is taken as five 250 mg tablets on an empty stomach and costs $2,900 per month.
The cost of new targeted cancer therapies - which can be as high as $10,000 per month - has generated substantial discussion and debate. "The economic implications of this food effect study are particularly remarkable. At the current price of $2,900 per month, this would have a cost savings of 60 percent or $1,740 per month" the commentary states. "As we enter an era of 'targeted' anticancer agents with a monthly cost measured in the thousands of dollars, we should view drug-drug or drug-food interactions as opportunities to lower costs."
The commentary states that rising cancer drug prices are encouraging researchers to explore such pharmacologic approaches to lowering costs. However, the authors urge that neither physicians nor patients consider changing lapatinib dose based on these findings, and that everyone strictly follow the prescribing label directions, which are based on the findings of rigorous clinical tests. The authors strongly emphasize that a formal pharmacokinetic study of a lower dose of lapatinib with food would need to confirm these findings before any change in dosage could be considered safe and effective.
American Society of Clinical Oncology
Lapatinib was approved by the U.S. Food and Drug Administration (FDA) in March of this year for women with advanced HER2-positive breast cancer. The FDA approved the 1,250 mg dose of lapatinib based on a large phase III clinical trial demonstrating its effectiveness and safety at that dose without food. It is taken as five 250 mg tablets on an empty stomach and costs $2,900 per month.
The cost of new targeted cancer therapies - which can be as high as $10,000 per month - has generated substantial discussion and debate. "The economic implications of this food effect study are particularly remarkable. At the current price of $2,900 per month, this would have a cost savings of 60 percent or $1,740 per month" the commentary states. "As we enter an era of 'targeted' anticancer agents with a monthly cost measured in the thousands of dollars, we should view drug-drug or drug-food interactions as opportunities to lower costs."
The commentary states that rising cancer drug prices are encouraging researchers to explore such pharmacologic approaches to lowering costs. However, the authors urge that neither physicians nor patients consider changing lapatinib dose based on these findings, and that everyone strictly follow the prescribing label directions, which are based on the findings of rigorous clinical tests. The authors strongly emphasize that a formal pharmacokinetic study of a lower dose of lapatinib with food would need to confirm these findings before any change in dosage could be considered safe and effective.
American Society of Clinical Oncology
Cancer Drug Current Events and Cancer Drug News RSSCancer drug effectively treats transplant rejections
University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.
Activating the lung's antioxidant defense by targeting Nrf2 inhibits the development of emphysema
Using a molecule similar to one found in an experimental cancer drug, researchers at the Johns Hopkins Bloomberg School of Public Health demonstrated that activation of a key component of the lung's antioxidant defense system, Nrf2, can prevent emphysema in mice.
Not Just for Depression Anymore
Prozac is regularly prescribed to ease the emotional pain of patients who are being treated for cancer. But can this common anti-depressant help to fight cancer itself?
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Herbal Menopause Therapy a Good Fit for Breast Cancer Patients?
When it comes to understanding the effectiveness and safety of using herbal therapies with other drugs, much is unknown. Now, a University of Missouri researcher will study how black cohosh - an herbal supplement often used to relieve hot flashes in menopausal women - interacts with tamoxifen, a common drug used to treat breast cancer.
Burnham Researchers Turn Cancer Friend into Cancer Foe
Burnham Institute for Medical Research today announced that scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer.
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.
Rare genetic disorder gives clues to autism, epilepsy, mental retardation
A rare genetic disorder called tuberous sclerosis complex (TSC) is yielding insight into a possible cause of some neurodevelopmental disorders: structural abnormalities in neurons, or brain cells.
The dietary supplement genistein can undermine breast cancer treatment
Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report.
As head and neck cancer risks evolve, more treatment options emerge
Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the New England Journal of Medicine.
More Cancer Drug Current Events and Cancer Drug News Articles
 | Gene Therapy for Cancer (Cancer Drug Discovery and Development) The possibility of treating cancer, a disease frequently defined bygenetic defects, by introducing genes that target these veryalterations has generated tremendous enthusiasm. This enthusiasm,however, has been tempered by an increasing number of obstacles tosuccessful therapy, including vector systems that do not reach systemicmetastases, therapeutic genes with redundant mechanisms allowing... |
| Physicians' Cancer Chemotherapy Drug Manual: 2009 (Jones and Bartlett Series in Oncology(physician's Cancer Che) by Edward Chu, Vincent DeVita Jr. Completely revised and updated for 2009, the Physicians Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in the clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens both on-and off-label... | |
 | American Cancer Society Consumer's Guide to Cancer Drugs, Second Edition (Jones and Bartlett Series in Oncology) by Gail Wilkes Current knowledge of the drugs used in cancer care is critical for today's practicing nurse. Drugs covered are described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations. Potential toxicities, side effects, and the nursing process are... |
 | Physician's Cancer Chemotherapy Drug Manual 2008 (Jones and Bartlett Series in Oncology) by Edward Chu, Vincent T. DeVita Jr. Completely revised and updated for 2008, this practical handbook is an up-to-date guide to all aspects of cancer chemotherapy. The book provides a comprehensive, easy to use catalogue of over 100 drugs-both on- and off-label-commonly used in cancer treatment. A section on Common Chemotherapy Regimens provides a quick reference to management of specific cancers, arranged... |
 | Cancer Drug Design and Discovery The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections... |
 | Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About by Ben A. Williams (Fairview Press) Univ. of California, San Diego. Consumer text explains how patients can improve their odds for survival by demanding control over their health care, research conventional and alternative treatments, creating their own treatment strategy, and using the Internet to learn of new medical advances.... |
 | Pocket Guide to Colorectal Cancer: Drugs and Treatment (Oncology Nursing Pocket Guide) by Gail M. Wilkes This small pocket guide focuses primarily on the drugs used for treatment and symptom management for colorectal cancer. It is easy to navigate and includes a brief overview of colorectal cancer and patient education information for each of the drugs. A must-have companion resource for oncology... |
 | Biomarkers in Breast Cancer (Cancer Drug Discovery and Development) Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design... |
 | Healing Cancer: Complementary Vitamin & Drug Treatments by Abram Hoffer, Linus Pauling Complementary vitamin supplement program for treating cancer and for supporting chemotherapy, radiation, and surgical treatments, with 100 case... |
| Drug Treatment of Cancer Pain in a Drug-Oriented Society (Advances in Pain Research and Therapy) |
| © 2009 BrightSurf.com |